Ovarian Cancer definition

Ovarian Cancer means epithelial ovarian cancer (serous, endometrioid, undifferentiated, clear cell, borderline and mucinous), fallopian tube cancer, or primary peritoneal cancer. For the avoidance of doubt, Ovarian Cancer includes Ovarian Cancer A through D.
Sample 1Sample 2Sample 3
Ovarian Cancer means the treatment and/or amelioration using the Licensed Product in patients having ovarian cancer who have become resistant to at least one cycle of chemotherapy and/or the prevention of such ovarian cancer in such patients using the Licensed Products.
Sample 1Sample 2Sample 3
Ovarian Cancer means epithelial cancer that originates in the ovaries, fallopian tubes, and/or peritoneum, with: (a) serious, endometrioid, clear cell, or undifferentiated subtype; or (b) a mixture of subtypes that includes one or more of the subtypes specified in the immediately preceding clause (a).
Sample 1

Examples of Ovarian Cancer in a sentence

  • Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer.

  • Notwithstanding the foregoing, in the event that Allarity has not enrolled and dosed at least thirty (30) patients with the first dose of cancer drug E7449 in the ongoing Phase 2 Ovarian Cancer Clinical Trial by July 1, 2022 then the Extension Payment shall become due and payable in full by July 30, 2022.

  • The Value of CA 125 Serum Assay in the Management of Ovarian Cancer.

  • Ovarian cancer has overall poor survival rates, compared with other gynecological cancers (World Ovarian Cancer Coalition, 2018).

  • Tumor Type Gastric Cancer Esophageal Cancer Head & Neck SCC Ovarian Cancer Hepatocellular Carcinoma Median Treatment Duration 45 days (4-457) 50 days (1-246) 104 days (30-339) 71 days (29-540) 64 days (1-471) Evaluable Patients N=34 N=31 N=17 N=50 N=27 PR Confirmed Unconfirmed 4 -- 2 3 3 -- 2 -- 1 2 SD 3 6 6 20 9 Pts Remaining on Treatment* 18 9 3 6 24 Source ESMO 20171 ESMO 20171 ESMO 20172 ESMO 20173 WCGI 20174 *At the time of the data cutoff.

  • Ovarian Cancer – AVALON phase 2B in patients with platinum-resistant ovarian cancer (IMV-sponsored)Globally, ovarian cancer is the seventh most diagnosed cancer among women and a leading cause of mortality among all gynecological cancers (Global Data: Ovarian Cancer Opportunity Analysis and Forecast to 2028).

  • Ovarian Cancer – DeCidE1 phase 2 in patients with recurrent, advanced platinum-sensitive and resistant ovarian cancer (IMV-sponsored)Globally, ovarian cancer is the seventh most diagnosed cancer among women and a leading cause of mortality among all gynecological cancers (Global Data: Ovarian Cancer Opportunity Analysis and Forecast to 2028).

  • Grisham, Iyer, Low - Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions; Curr Treat Options Oncology; 2018; Globocan 2020 2 Patient - months of Therapy metric calculated by multiplying relevant incidence/prevalence rate times estimated duration of thera py; represents US market opportunity only; patient population estimates from Globocan 2020, American Cancer Society 2021, AACR Genie Cohort 9.0 public, and scientific publications.

  • Potential Synergistic Benefit of Dovitinib + Stenoparib in 2 nd line or later HR Proficient Ovarian Cancer; Phase 1b Dosing Study Initiated in Q1 2023 16 Allarity Therapeutics Stenoparib: Phase 1b Combo Study with Dovitinib in Solid Tumors Ongoing Phase 1b Combination Study: Potential Synergistic Benefit of Dovitinib + Stenoparib in Solid Tumors; Data Readout Anticipated in H1 2024 * • Ongoing Phase 1b combination therapy study in advanced solid tumors.

  • Grisham, Iyer, Low - Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions; Curr Treat Options Oncology; 2018.

Related to Ovarian Cancer

  • Stage-Four Advanced, Metastatic Cancer means a cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other areas or parts of the body.

  • Receptor means enclosed spaces, conduits, protected groundwater sources, drinking and non-drinking water wells, surface water bodies, and public water systems which when impacted by chemicals of concern may result in exposure to humans and aquatic life, explosive conditions or other adverse effects on health, safety and the environment as specified in these rules.